951 related articles for article (PubMed ID: 18310297)
1. Role of positron emission tomography and bone scintigraphy in the evaluation of bone involvement in metastatic pheochromocytoma and paraganglioma: specific implications for succinate dehydrogenase enzyme subunit B gene mutations.
Zelinka T; Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Reynolds JC; Ling A; Eisenhofer G; Lazúrová I; Adams KT; Whatley MA; Widimsky J; Pacak K
Endocr Relat Cancer; 2008 Mar; 15(1):311-23. PubMed ID: 18310297
[TBL] [Abstract][Full Text] [Related]
2. Superiority of fluorodeoxyglucose positron emission tomography to other functional imaging techniques in the evaluation of metastatic SDHB-associated pheochromocytoma and paraganglioma.
Timmers HJ; Kozupa A; Chen CC; Carrasquillo JA; Ling A; Eisenhofer G; Adams KT; Solis D; Lenders JW; Pacak K
J Clin Oncol; 2007 Jun; 25(16):2262-9. PubMed ID: 17538171
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 18F-fluoro-L-DOPA, 18F-fluoro-deoxyglucose, and 18F-fluorodopamine PET and 123I-MIBG scintigraphy in the localization of pheochromocytoma and paraganglioma.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Havekes B; Eisenhofer G; Martiniova L; Adams KT; Pacak K
J Clin Endocrinol Metab; 2009 Dec; 94(12):4757-67. PubMed ID: 19864450
[TBL] [Abstract][Full Text] [Related]
4. Failure of MIBG scan to detect metastases in SDHB-mutated pediatric metastatic pheochromocytoma.
Sait S; Pandit-Taskar N; Modak S
Pediatr Blood Cancer; 2017 Nov; 64(11):. PubMed ID: 28409892
[No Abstract] [Full Text] [Related]
5. Utility of FDG-PET imaging in screening for succinate dehydrogenase B and D mutation-related lesions.
Kornaczewski ER; Pointon OP; Burgess JR
Clin Endocrinol (Oxf); 2016 Aug; 85(2):172-9. PubMed ID: 26776272
[TBL] [Abstract][Full Text] [Related]
6. Screening in asymptomatic SDHx mutation carriers: added value of ¹⁸F-FDG PET/CT at initial diagnosis and 1-year follow-up.
Lepoutre-Lussey C; Caramella C; Bidault F; Déandreis D; Berdelou A; Al Ghuzlan A; Hartl D; Borget I; Gimenez-Roqueplo AP; Dumont F; Deschamps F; Nascimento C; Lumbroso J; Guillaud Bataille M; Schlumberger M; Baudin E; Leboulleux S
Eur J Nucl Med Mol Imaging; 2015 May; 42(6):868-76. PubMed ID: 25676472
[TBL] [Abstract][Full Text] [Related]
7. Superiority of
Jha A; Ling A; Millo C; Gupta G; Viana B; Lin FI; Herscovitch P; Adams KT; Taïeb D; Metwalli AR; Linehan WM; Brofferio A; Stratakis CA; Kebebew E; Lodish M; Civelek AC; Pacak K
Eur J Nucl Med Mol Imaging; 2018 May; 45(5):787-797. PubMed ID: 29204718
[TBL] [Abstract][Full Text] [Related]
8. Semiquantitative 123I-Metaiodobenzylguanidine Scintigraphy to Distinguish Pheochromocytoma and Paraganglioma from Physiologic Adrenal Uptake and Its Correlation with Genotype-Dependent Expression of Catecholamine Transporters.
van Berkel A; Rao JU; Lenders JW; Pellegata NS; Kusters B; Piscaer I; Hermus AR; Plantinga TS; Langenhuijsen JF; Vriens D; Janssen MJ; Gotthardt M; Timmers HJ
J Nucl Med; 2015 Jun; 56(6):839-46. PubMed ID: 25883126
[TBL] [Abstract][Full Text] [Related]
9. Superiority of [68Ga]-DOTATATE PET/CT to Other Functional Imaging Modalities in the Localization of SDHB-Associated Metastatic Pheochromocytoma and Paraganglioma.
Janssen I; Blanchet EM; Adams K; Chen CC; Millo CM; Herscovitch P; Taieb D; Kebebew E; Lehnert H; Fojo AT; Pacak K
Clin Cancer Res; 2015 Sep; 21(17):3888-95. PubMed ID: 25873086
[TBL] [Abstract][Full Text] [Related]
10. Staging and functional characterization of pheochromocytoma and paraganglioma by 18F-fluorodeoxyglucose (18F-FDG) positron emission tomography.
Timmers HJ; Chen CC; Carrasquillo JA; Whatley M; Ling A; Eisenhofer G; King KS; Rao JU; Wesley RA; Adams KT; Pacak K
J Natl Cancer Inst; 2012 May; 104(9):700-8. PubMed ID: 22517990
[TBL] [Abstract][Full Text] [Related]
11. Functional imaging of SDHx-related head and neck paragangliomas: comparison of 18F-fluorodihydroxyphenylalanine, 18F-fluorodopamine, 18F-fluoro-2-deoxy-D-glucose PET, 123I-metaiodobenzylguanidine scintigraphy, and 111In-pentetreotide scintigraphy.
King KS; Chen CC; Alexopoulos DK; Whatley MA; Reynolds JC; Patronas N; Ling A; Adams KT; Xekouki P; Lando H; Stratakis CA; Pacak K
J Clin Endocrinol Metab; 2011 Sep; 96(9):2779-85. PubMed ID: 21752889
[TBL] [Abstract][Full Text] [Related]
12. Correlation of the genotype of paragangliomas and pheochromocytomas with their metabolic phenotype on 3,4-dihydroxy-6-18F-fluoro-L-phenylalanin PET.
Rischke HC; Benz MR; Wild D; Mix M; Dumont RA; Campbell D; Seufert J; Wiech T; Rössler J; Weber WA; Neumann HP
J Nucl Med; 2012 Sep; 53(9):1352-8. PubMed ID: 22836345
[TBL] [Abstract][Full Text] [Related]
13. Genetic status determines
Tiwari A; Shah N; Sarathi V; Malhotra G; Bakshi G; Prakash G; Khadilkar K; Pandit R; Lila A; Bandgar T
J Med Imaging Radiat Oncol; 2017 Dec; 61(6):745-752. PubMed ID: 28585398
[TBL] [Abstract][Full Text] [Related]
14. 6-18F-fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to 123I-metaiodobenzyl-guanidine scintigraphy in the detection of extraadrenal and hereditary pheochromocytomas and paragangliomas: correlation with vesicular monoamine transporter expression.
Fottner C; Helisch A; Anlauf M; Rossmann H; Musholt TJ; Kreft A; Schadmand-Fischer S; Bartenstein P; Lackner KJ; Klöppel G; Schreckenberger M; Weber MM
J Clin Endocrinol Metab; 2010 Jun; 95(6):2800-10. PubMed ID: 20371665
[TBL] [Abstract][Full Text] [Related]
15. 6-[F-18]Fluoro-L-dihydroxyphenylalanine positron emission tomography is superior to conventional imaging with (123)I-metaiodobenzylguanidine scintigraphy, computer tomography, and magnetic resonance imaging in localizing tumors causing catecholamine excess.
Fiebrich HB; Brouwers AH; Kerstens MN; Pijl ME; Kema IP; de Jong JR; Jager PL; Elsinga PH; Dierckx RA; van der Wal JE; Sluiter WJ; de Vries EG; Links TP
J Clin Endocrinol Metab; 2009 Oct; 94(10):3922-30. PubMed ID: 19622618
[TBL] [Abstract][Full Text] [Related]
16. False-negative ¹²³I-MIBG SPECT is most commonly found in SDHB-related pheochromocytoma or paraganglioma with high frequency to develop metastatic disease.
Fonte JS; Robles JF; Chen CC; Reynolds J; Whatley M; Ling A; Mercado-Asis LB; Adams KT; Martucci V; Fojo T; Pacak K
Endocr Relat Cancer; 2012 Feb; 19(1):83-93. PubMed ID: 22167067
[TBL] [Abstract][Full Text] [Related]
17. Mutation analysis of SDHB and SDHC: novel germline mutations in sporadic head and neck paraganglioma and familial paraganglioma and/or pheochromocytoma.
Bayley JP; van Minderhout I; Weiss MM; Jansen JC; Oomen PH; Menko FH; Pasini B; Ferrando B; Wong N; Alpert LC; Williams R; Blair E; Devilee P; Taschner PE
BMC Med Genet; 2006 Jan; 7():1. PubMed ID: 16405730
[TBL] [Abstract][Full Text] [Related]
18. Aggressive Imaging Features in a Malignant Pheochromocytoma With a Novel Mutation of the SDHB Gene.
Park SA; Lee DH; Kim HS
Clin Nucl Med; 2017 Sep; 42(9):687-689. PubMed ID: 28650885
[TBL] [Abstract][Full Text] [Related]
19. Detection of metastatic lesions from malignant pheochromocytoma and paraganglioma with diffusion-weighted magnetic resonance imaging: comparison with 18F-FDG positron emission tomography and 123I-MIBG scintigraphy.
Takano A; Oriuchi N; Tsushima Y; Taketomi-Takahashi A; Nakajima T; Arisaka Y; Higuchi T; Amanuma M; Endo K
Ann Nucl Med; 2008 Jun; 22(5):395-401. PubMed ID: 18600417
[TBL] [Abstract][Full Text] [Related]
20. SDHB mutations are associated with response to temozolomide in patients with metastatic pheochromocytoma or paraganglioma.
Hadoux J; Favier J; Scoazec JY; Leboulleux S; Al Ghuzlan A; Caramella C; Déandreis D; Borget I; Loriot C; Chougnet C; Letouzé E; Young J; Amar L; Bertherat J; Libé R; Dumont F; Deschamps F; Schlumberger M; Gimenez-Roqueplo AP; Baudin E
Int J Cancer; 2014 Dec; 135(11):2711-20. PubMed ID: 24752622
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
